The Molecular Biology of Soft-Tissue Sarcomas and Current Trends in Therapy

Abstract EN

Basic research in sarcoma models has been fundamental in the discovery of scientific milestones leading to a better understanding of the molecular biology of cancer.

Yet, clinical research in sarcoma has lagged behind other cancers because of the multiple clinical and pathological entities that characterize sarcomas and their rarity.

Sarcomas encompass a very heterogeneous group of tumors with diverse pathological and clinical overlapping characteristics.

Molecular testing has been fundamental in the identification and better definition of more specific entities among this vast array of malignancies.

A group of sarcomas are distinguished by specific molecular aberrations such as somatic mutations, intergene deletions, gene amplifications, reciprocal translocations, and complex karyotypes.

These and other discoveries have led to a better understanding of the growth signals and the molecular pathways involved in the development of these tumors.

These findings are leading to treatment strategies currently under intense investigation.

Disruption of the growth signals is being targeted with antagonistic antibodies, tyrosine kinase inhibitors, and inhibitors of several downstream molecules in diverse molecular pathways.

Preliminary clinical trials, supported by solid basic research and strong preclinical evidence, promises a new era in the clinical management of these broad spectrum of malignant tumors.